MFMichael Findler

Michael Findler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Findler has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Quantitative Perihematomal Imaging Analysis for the Prediction of Intracerebral Hematoma Expansion

    by Yuval Wiesel, Michael Findler, Jonathan Naftali, Asaf Honig, Rani Barnea, Eitan Auriel

    Hematoma expansion (HE) is a major cause of early neurological deterioration and poor outcome in spontaneous intracerebral hemorrhage (ICH). The perihematomal region (PHR), a potential site of secondary vascular injury, remains poorly characterized. We evaluated whether quantitative PHR features provide predictive information for HE beyond hematoma features and insight into HE dynamics. In this retrospective two-center study, 149 patients with acute ICH underwent baseline CT within 24 hours of symptom onset and follow-up CT within 72 hours. HE was defined as >6 mL or >33% hematoma growth on follow-up CT. Hematoma and perihematomal regions were segmented using relative (half- and full-radius) and absolute (2, 5, and 10 mm) definitions. Radiomic features were extracted and modeled using multivariable logistic regression. Clinical predictors were added to create combined clinical-radiomic models, and performance was evaluated on an independent test set. HE occurred in 29% (44/149) of patients. The hematoma-only radiomic model showed modest discrimination (AUC=0.71, 95% CI 0.62-0.80). Incorporating PHR features improved performance, with the absolute 5-mm PHR model achieving the highest discrimination (AUC=0.91, 95% CI 0.86-0.95). Adding clinical predictors further enhanced performance (AUC=0.94, 95% CI 0.90-0.97). Key PHR features associated with HE included reduced sphericity, increased texture coarseness, and clustered heterogeneity. Quantitative PHR characterization was strongly associated with HE and provided incremental value beyond hematoma-derived radiomics, with further improvement when combined with clinical predictors. This contrast-free approach may support objective risk stratification, guide targeted interventions and reduce expansion related morbidity.

  • Open Access

    Long-term clinical follow-up of intracranial aneurysms treated with flow diverter devices: a bicentric retrospective study

    by Mahmoud Moubark, Alessandra Biondi, Moustafa Othman, Michael Findler, Giovanni Vitale, Francis Turjman

    Background: Flow diverter devices (FDDs) have revolutionized the treatment of intracranial aneurysms. However, comprehensive long-term outcome data across multiple device platforms remain limited, with most prior studies focusing exclusively on Pipeline embolization device (PED) outcomes. This study reports extensive long-term clinical follow-up of patients treated with various types of FDDs, providing critical safety and efficacy data for contemporary practice. Methods: We conducted a retrospective analysis of intracranial aneurysms treated with FDDs from February 2011 to July 2016 in two tertiary care centers in France. The study included 209 patients with 216 cerebral aneurysms (91.2% anterior circulation, 8.8% posterior circulation; 66.2% unruptured, 31.0% recanalized, 2.8% ruptured). The duration of clinical and angiographic follow-up ranged from 24 to 156 months. Kaplan–Meier analysis performed for complication-free survival and aneurysm occlusion durability. Multivariate analysis showed risk factors for delayed complications. Results: Long-term follow-up data were available for 202/209 (96.7%) patients. The early permanent morbidity and mortality rates were 3.8% and 1.4%, respectively. Between 12 and 18 months, procedure-related complications occurred in 5 of 202 patients (2.5%): two ischemic events, one delayed rupture, one silent intrastent stenosis, and one case of seizures following antiplatelet withdrawal. Only three patients (1.5%) were symptomatic. At the 24-month follow-up, complete aneurysm occlusion achieved in 81.0% of the patients, with adequate occlusion in 93.3%. Kaplan–Meier analysis revealed 97.5% complication-free survival at 18 months, with sustained durability thereafter. Multiple FDDs were the only significant independent predictor of delayed complications (OR: 7.066, 95% CI: 1.049–47.606, P < 0.045). No procedure-related complications or deaths occurred after 18 months. Conclusion: Beyond 18 months of follow-up, FDD treatment for intracranial aneurysms proves exceptional safety with no delayed complications, regardless of device type. However, the findings of this study also show 18 months as a critical threshold for complication risk assessment, a key implication that clinicians and researchers need to be aware of. The study also underscores the need for modified management strategies when multiple overlapping FDDs are deployed, which significantly increases the risk of delayed complications.

  • Challenging the limits of angioplasty: Comaneci device for distal vasospasm following subarachnoid hemorrhage

    by Chen Meir Kadosh, Michael Findler, Ran Brauner, José De Obaldía, Alain Perlow, Harel Tziperman, Sagi Harnof, Guy Raphaeli

    Introduction: Aneurysmal subarachnoid hemorrhage (aSAH) is often complicated by delayed cerebral vasospasm (DCV), a major cause of morbidity and mortality. Balloon angioplasty is standard for refractory cases but carries a high risk in distal vessels. This study reports preliminary single-center experience with the Comaneci device for DCV, emphasizing distal segments beyond the circle of Willis, where evidence remains limited. Methods: We retrospectively analyzed patients with aSAH and symptomatic DCV refractory to medical therapy treated with Comaneci-assisted angioplasty (CAA). Demographic, procedural, clinical, and angiographic data were collected from electronic records. Angiographic response was graded using a vasospasm severity scale. Results: CAA was performed in 94 vessels across 14 patients (median age 63 years; 85.7% female). Severe-to-critical vasospasm was present in 88.6%. Most interventions involved the anterior circulation (79.1%), with distal segments (M2 and A2–A4) comprising 54.1%. The M2 segment was most frequently treated (36.4%). Patients underwent a median of three interventions (range 2–6). Angioplasty resulted in significant resolution of vasospasm in 92.7% of vessels, with retreatment required in 8.3%. At 6 months, a favorable outcome (mRS 0–2) was observed in 51.5% of patients, while 90-day mortality was 21.4%. No vessel perforations or long-term complications occurred; one transient occlusion was successfully managed with aspiration. Conclusions: CAA appears feasible and safe for DCV, particularly in the distal vasculature where balloon angioplasty is rarely used. These findings suggest the device may provide a valuable alternative to conventional therapy. Larger prospective studies are required to confirm safety, efficacy, and long-term clinical impact.


  • Open Access

    3D printed aneurysm training before treatment: A case control retrospective study

    by Mishel Manashirov, Ran Brauner, Yarden Mor, Guy Raphaeli, Sagi Harnof, Alain Perlow, Eitan Auriel, Michael Findler

  • Significance of cerebral microinfarcts in antiphospholipid syndrome: A population-based study

    by Jonathan Naftali, Rani Barnea, Ruth Eliahou, Walid Saliba, Sivan Bloch, Michael Findler, Ran Brauner, Tzippy Shochat, Avi Leader, Eitan Auriel

    Background: Acute ischemic stroke (AIS) or transient ischemic attack (TIA) is the most common neurological manifestations of patients with antiphospholipid syndrome (APS). Incidental diffusion-weighted imaging (DWI) positive subcortical and cortical lesions, or acute incidental cerebral microinfarcts (CMI), are microscopic ischemic lesions, detectable on MRI for 10–14 days only. We aimed to look at the prevalence of acute incidental CMI in a cohort of patients with APS and their association with subsequent AIS or TIA. Methods: This is a population-based cohort study of adults with APS diagnosis using International Statistical Classification-9 (ICD-9) and supporting laboratory results between January 2014 and April 2020. We included any patient undergoing brain MRI (index event) during the year prior APS diagnosis or at any time point following diagnosis. Age-matched subjects with negative APS laboratory workup were used as a control group. In the first analysis, we compared acute incidental CMI prevalence in both groups. We then performed a second analysis among APS patients only, comparing patients with and without acute incidental CMI for AIS or TIA as the primary outcome. Cox proportional hazards models used to calculate hazards ratio (HR) and 4 years cumulative risk. Results: 292 patients were included, of which, 207 patients with APS. Thirteen patients with APS had acute incidental CMI on MRI (6.3%), compared with none in the control group ( p = 0.013). Following multivariable analysis, APS was the sole factor associated with acute incidental CMI ( p = 0.026). During a median follow-up of 4 years (IQR 3.5, 4) in patients with APS, following multivariable analysis, acute incidental CMI was associated with subsequent AIS or TIA (HR 6.73 [(95% CI, 1.96–23.11], p < 0.01). Conclusion: Acute incidental CMI are more common among patients with APS than in patients with negative APS tests, and are associated with subsequent AIS or TIA. Detecting acute incidental CMI in patients with APS may guide etiological workup and reevaluation of antithrombotic regimen.


  • Open Access

    Safety and efficacy of acute ischemic stroke intervention in patients with cognitive decline: case‐control retrospective study

    by Jonathan Naftali, Eitan Auriel, Keshet Prado, Gal Tzur, Rani Barnea, Michael Findler, Guy Rephaely, Alin Perlov, Amir Glik, Ophir Keret

    Background: Individuals diagnosed with mild cognitive impairment and dementia (MCI/Dem) are excluded from research on intervention for acute ischemic stroke; This research gap places stroke physicians worldwide in dilemmas while treating patients with cognitive decline. One example is acute stroke of large brain arteries, typically manifesting as immediate onset of severe neurological disability. Endovascular treatment (EVT), aka catheter‐base clot removal, is considered the gold‐standard treatment and when applied within hours after onset, can mitigate or reverse deficits and dramatically improve outcomes. Our goal was to evaluate efficacy and safety of EVT for acute stroke in MCI/Dem.Methods: This is a single site retrospective study from Rabin Medical Center,2019‐2021. Inclusion criteria was new onset acute large vessel stroke receiving EVT treatment, ages 18‐85 years. Pre‐stroke cognitive status was assessed using previous diagnosis, assessments in geriatric / occupational therapy clinics, nurse functional questionnaire and rehabilitation interview. Individuals were dichotomized to MCI/Dem (any severity) and unimpaired via consensus between two behavioural neurologists. The MCI/Dem group was matched to unimpaired individuals for sex, age, pre‐stroke functional independence, and stroke arterial territory, severity and time to EVT. The outcomes were retrospectively assessed 90 days after stroke and included mortality, intracranial haemorrhage, and pre to post stroke difference in the modified Rankin scale (mRS), commonly used instrument for stroke functional independence.Results: We identified 306 individuals with acute large vessel stroke who underwent EVT, of which 32 with pre‐stroke MCI/Dem. After matching, we saw no differences between non impaired group to MCI/Dem group in functional outcome measured by mRS change, (56% vs.53%, p = 0.8), brain hemorrhage(22% vs. 9%, p = 0.68) and mortality (25% vs. 12%,p = 0.2).Conclusion: To our knowledge this is the first study to report on EVT outcomes in individuals with MCI/Dem. Our results suggest interventions for acute large vessel stroke may have similar efficacy and safety profile in individuals with pre‐stroke MCI/Dementia and thus challenge previous recommendations to exclude them from therapy. Our data is retrospective and thus of inadequate design to suggest change to clinical guidelines. Further research on stroke interventions in MCI/Dem is urgently needed to guide day‐to‐day clinical decision making

  • Delayed CTP-Derived Deep Venous Outflow: A Novel Predictor of Striatocapsular Infarction after M1 Thrombectomy

    by S. Peretz, K. Pardo, J. Naftali, M. Findler, G. Raphaeli, R. Barnea, V. Khasminsky, E. Auriel

    BACKGROUND AND PURPOSE: Isolated striatocapsular infarction occurs commonly in patients with ischemic stroke following M1 thrombectomy. We aimed to explore the correlation between CTP-derived parameters of deep venous outflow at presentation and subsequent striatocapsular infarction in a retrospective cohort of such patients. MATERIALS AND METHODS: TTP and peak enhancement were measured on CTP-derived time-attenuation curves of the internal cerebral and thalamostriate veins bilaterally. The difference in TTP (ΔTTP) and the relative decrease in venous enhancement between the ischemic and normal sides were calculated. NCCT performed 24 (SD, 12) hours postthrombectomy was used to determine tissue fate in the caudate head, caudate body, lentiform nucleus, and internal capsule. Striatocapsular ischemia (striatocapsular infarction–positive) was defined as infarction and striatocapsular injury as either infarction, contrast enhancement, or hemorrhagic transformation in ≥1 of these regions. A striatocapsular ischemia score was calculated (0 = no ischemic region, 1 = 1 ischemic region, 2 = ≥2 ischemic regions). RESULTS: One hundred sixteen patients were included in the analysis. Sixty-one patients had striatocapsular infarction (striatocapsular infarction–positive). The mean thalamostriate ΔTTP was 1.95 (SD, 1.9) seconds for patients positive for striatocapsular infarction and 0.79 (SD, 2.1) for patients negative for it (P = .010). Results were similar for striatocapsular injury. The mean thalamostriate ΔTTP was 0.79 (SD, 2.1), 1.68 (SD, 1.4), and 2.05 (SD, 2) for striatocapsular infarction scores of 0, 1, and 2, respectively (P = .030). CONCLUSIONS: CTP-derived thalamostriate ΔTTP is an excellent surrogate marker for striatocapsular infarction in patients post-M1 thrombectomy. The novel approach of extracting venous outflow parameters from CTP has numerous potential applications and should be further explored.


  • Open Access

    A Novel Rodent Model of Hypertensive Cerebral Small Vessel Disease with White Matter Hyperintensities and Peripheral Oxidative Stress

    by Reut Guy, Rotem Volkman, Ella Wilczynski, Chana Yagil, Yoram Yagil, Michael Findler, Eitan Auriel, Uri Nevo, Daniel Offen

    Cerebral small vessel disease (CSVD) is the second most common cause of stroke and a major contributor to dementia. Manifestations of CSVD include cerebral microbleeds, intracerebral hemorrhages (ICH), lacunar infarcts, white matter hyperintensities (WMH) and enlarged perivascular spaces. Chronic hypertensive models have been found to reproduce most key features of the disease. Nevertheless, no animal models have been identified to reflect all different aspects of the human disease. Here, we described a novel model for CSVD using salt-sensitive ‘Sabra’ hypertension-prone rats (SBH/y), which display chronic hypertension and enhanced peripheral oxidative stress. SBH/y rats were either administered deoxycorticosteroid acetate (DOCA) (referred to as SBH/y-DOCA rats) or sham-operated and provided with 1% NaCl in drinking water. Rats underwent neurological assessment and behavioral testing, followed by ex vivo MRI and biochemical and histological analyses. SBH/y-DOCA rats show a neurological decline and cognitive impairment and present multiple cerebrovascular pathologies associated with CSVD, such as ICH, lacunes, enlarged perivascular spaces, blood vessel stenosis, BBB permeability and inflammation. Remarkably, SBH/y-DOCA rats show severe white matter pathology as well as WMH, which are rarely reported in commonly used models. Our model may serve as a novel platform for further understanding the mechanisms underlying CSVD and for testing novel therapeutics.


  • Interobserver Agreement in Scoring Angiographic Results of Basilar Artery Occlusion Stroke Therapy

    by M. Findler, A.S. Turjman, J. Raymond, P.M. White, U. Sadeh-Gonik, C.A. Taschner, M. Mazighi, A. Biondi, B. Gory, F. Turjman

    BACKGROUND AND PURPOSE: The modified TICI Infarction grading system is a metric currently used to evaluate angiographic results of thrombectomy for large-vessel occlusion in ischemic stroke. Originally designed for evaluating MCA territories, it is currently used for other vessel occlusions, including the posterior circulation. We postulate that the modified TICI use for the posterior circulation is not accurate due to the different vascular territories supplied by vertebrobasilar vasculature, making grading more complex. MATERIALS AND METHODS: We collected angiographic results from 30 patients who presented with acute posterior circulation occlusions between 2015 and 2018 and underwent thrombectomy in our institution. Eight observers were asked to evaluate the TICI scores before and after thrombectomy. The multirater statistics were computed using Fleiss κ analysis. Further data were collected regarding the potential brain territories at risk and the existence of atherosclerotic disease in the basilar artery. RESULTS: The overall agreement κ reached 0.277 (SD, 0.013), which suggests a “fair” agreement among the raters. On average, 45% of observers achieved a high accuracy in predicting brain areas at risk of ischemia. As for the existence of basilar atherosclerotic disease, a high agreement (defined as at least 5 of 6 observers) was seen in 20 of the 30 patients. CONCLUSIONS: Despite TICI being ubiquitous in stroke diagnostics, the high variability of posterior circulation TICI scores calls into question its use in these strokes. Other methods should be developed to assess recanalization in the posterior circulation.


  • Open Access

    Effects of Head‐Up Tilt‐Table Test on the QT Interval

    by Michael Findler, Amir Birger, Shmuel Diamant, Sami Viskin

    Background. The QT interval shortens in response to sympathetic stimulation and its response to epinephrine infusion (in healthy individuals and patients with long QT syndrome) has been thoroughly studied. Head‐up tilt‐table (HUT) testing is an easy way to achieve brisk sympathetic stimulation. Yet, little is known about the response of the QT interval to HUT. Methods. We reviewed the electrocardiograms of HUT tests performed at our institution and compare the heart rate, QT, and QTc obtained immediately after HUT with the rest values. Results. The study group consisted of 41 patients (27 females and 14 males) aged 23.9 ± 8.4 years. Head‐up tilting led to a significant shortening of the RR interval (from 825 ± 128 msec at rest phase to 712 ± 130 msec in the upward tilt phase, P < 0.001) but only to a moderate shortening of the QT interval (from 363.7 ± 27.9 msec during rest to 355 ± 30.3 msec during upward tilt, P = 0.001). Since the RR interval shortened more than the QT interval, the QTc actually increased (from 403 ± 21.5 msec during rest phase to 423.2 ± 27.4 msec during upward tilt, P < 0.001). The QTc value measured for the upward tilt position was longer than the resting QTc value in 33 of 41 patients. Of those, 4 male patients and 2 female patients developed upward‐tilt QTc values above what would be considered abnormal at rest. Conclusions. During HUT the QT shortens less than the RR interval. Consequently, the QTc increases during head‐up tilt. Ann Noninvasive Electrocardiol 2010;15(3):245–249